Forte Biosciences (FBRX) Capital Expenditures Growth (1y) (2017 - 2025)
Forte Biosciences (FBRX) Capital Expenditures Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -27.93% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Forte Biosciences | 174.08 Mn | 115.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 916.67% |
| Dec 31, 2024 | 82.35% |
| Dec 31, 2019 | 127.13% |
| Sep 30, 2019 | 109.70% |
| Jun 30, 2019 | -98.68% |
| Mar 31, 2019 | -42.22% |
| Dec 31, 2018 | -166.40% |
| Sep 30, 2018 | -813.46% |
| Jun 30, 2018 | 914.63% |
| Mar 31, 2018 | 66.67% |
| Dec 31, 2017 | 4,840.00% |
| Sep 30, 2017 | -67.50% |
| Jun 30, 2017 | -73.89% |
| Mar 31, 2017 | -34.15% |